“…However, the limited access to HAV vaccines in nonendemic countries led to vaccine shortages during outbreaks. (5,21,22) Delivery of two-dose HAV vaccines was separated by at least 6 months and used HAVRIX 1440 enzymelinked immunosorbent assay units (GlaxoSmithKline, Biologicals, Rixensart, Belgium), which was substituted by VAQTA 50 units (Merck and Co., Inc., West Point, PA) since May 19, 2016, due to a shortage of HAVRIX. After vaccination, follow-up of anti-HAV IgG was determined between 4 and 24 weeks; afterward, the second dose of HAV vaccine was administered, followed by the determinations of anti-HAV IgG at weeks 28-36 and 48.…”